3 million children across the Sahel region benefit from Seasonal Malaria Chemoprevention

Seasonal malaria chemoprevention (SMC) is defined as the intermittent administration of full treatment courses of an antimalarial medicine during the malaria season to prevent malarial illness with the objective of maintaining therapeutic antimalarial drug concentrations in the blood throughout the period of greatest malarial transmission.1

WHO recommends SMC using a complete treatment of sulfadoxine-pyrimethamine and amodiaquine (SP+AQ) once a month for 4 months during the malaria transmission season for children aged between 3 and 59 months.

ACCESS-SMC is a UNITAID-funded project led by Malaria Consortium which is supporting National Malaria Control Programmes in seven countries in the Sahel region to roll out SMC. Thanks to this project, in 2015 three million children received SMC medication2 to prevent malaria in the Sahel region with consequent reduction of malaria cases during the transmission period (preliminary results). MMV is a partner in the ACCESS-SMC project and is focusing primarily on strengthening and diversifying the supply-side response to increasing demand for SPAQ. 


1. WHO Policy Recommendation: Seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa 

2. sulfadoxine-pyrimethamine+amodiaquine, supplied by MMV's partner Guilin Pharma